Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab

References

• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology132(7), 2557–2576 (2007).
   PubMed Web of Science ®Google Scholar
• Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell5(3), 215–219 (2004).
   PubMed Web of Science ®Google Scholar
• Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis.11(1), 191–207, x–xi (2007).
   PubMedGoogle Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med.340(10), 745–750 (1999).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology42(5), 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. Clin. Liver Dis.9(2), 301–314, viii (2005).
   PubMedGoogle Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology37(2), 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol.23(13), 2892–2899 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J. Clin. Oncol.23(31), 8093–8108 (2005).
   PubMed Web of Science ®Google Scholar
• Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatol. Res.37(Suppl. 2), S230–S237 (2007).
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS94, 209–231 (2005).
   Google Scholar
• Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol.116(6), 838–845 (2001).
   PubMed Web of Science ®Google Scholar
• Dhar DK, Naora H, Yamanoi A et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res.22(1A), 379–386 (2002).
   PubMed Web of Science ®Google Scholar
• Moon WS, Rhyu KH, Kang MJ et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod. Pathol.16(6), 552–557 (2003).
   PubMed Web of Science ®Google Scholar
• Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res.63(12), 3121–3126 (2003).
   PubMed Web of Science ®Google Scholar
• Jeng KS, Sheen IS, Wang YC et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol.10(5), 643–648 (2004).
   PubMed Web of Science ®Google Scholar
• Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol.10(4), 355–362 (2003).
   PubMed Web of Science ®Google Scholar
• Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol.14(6), 1835–1845 (2007).
   PubMed Web of Science ®Google Scholar
• Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin. Cancer Res.9(14), 5339–5345 (2003).
   PubMed Web of Science ®Google Scholar
• Chiang DY, Villanueva A, Hoshida Y et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res.68(16), 6779–6788 (2008).
   PubMed Web of Science ®Google Scholar
• Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res.65(9), 3691–3699 (2005).
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Fargnoli J et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res.14(19), 6146–6153 (2008).
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res.66(24), 11851–11858 (2006).
   PubMed Web of Science ®Google Scholar
• Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int.29(2), 284–290 (2009).
   PubMed Web of Science ®Google Scholar
• Huynh H, Chow PK, Palanisamy N et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J. Hepatol.49(1), 52–60 (2008).
   PubMed Web of Science ®Google Scholar
• Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J. Hepatol.49(6), 977–984 (2008).
   PubMed Web of Science ®Google Scholar
• Hao JH, Yu M, Li HK, Shi YR, Li Q, Hao XS. Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo. World J. Gastroenterol.12(7), 1140–1143 (2006).
   PubMedGoogle Scholar
• Huang J, Frischer JS, Serur A et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl Acad. Sci. USA100(13), 7785–7790 (2003).
   PubMed Web of Science ®Google Scholar
• Okamoto K, Neureiter D, Alinger B et al. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int. J. Oncol.33(4), 733–742 (2008).
   PubMed Web of Science ®Google Scholar
• Fuchs BC, Fujii T, Dorfman JD et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res.68(7), 2391–2399 (2008).
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol.26(18), 2992–2998 (2008).
   PubMed Web of Science ®Google Scholar
• Malka D, Dromain C, Farace F et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC). Preliminary results of a Phase II study with circulating endothelial cell (CEC) monitoring. J. Clin. Oncol.25(18 Suppl.), 4570 (2007).
   Google Scholar
• Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10(2), 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24(12), 1898–1903 (2006).
   PubMed Web of Science ®Google Scholar
• Sun W HD, Mykulowycz K, Rosen M et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC). A Phase II study. J. Clin. Oncol.25(18 Suppl.), 4574 (2007).
   Google Scholar
• Hsu C, Yang T, Hsu H et al. Phase II study of bevacizumab (A) plus capacitabine (X) in patients (pts) with advanced/ metastatic hepatocellular carcinoma (HCC), final report. J. Clin. Oncol.26(20 Suppl.), 4603 (2008).
   PubMedGoogle Scholar
• Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol.27(6), 843–850 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early anti-angiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist13(2), 120–125 (2008).
   PubMedGoogle Scholar
• Britten CD, Finn RS, Gomes, AS et al. A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization. J. Clin. Oncol.23(16 Suppl.), 4138 (2005).
   Google Scholar